Healing of erosive esophagitis with sucralfate and cimetidine: Influence of pretreatment lower esophageal sphincter pressure and serum pepsinogen I levels

Ros, Emilio; Toledo-Pimentel, V; Bordas, Josep M.; Grande, Luís; Lacima, Gloria; Segú, Luis

doi:10.1016/0002-9343(91)90460-f

Cited by 11 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sucralfate was as effective as Gaviscon containing sodium alginate with regard to healing of esophagitis and symptomatic improvement . The H 2 RAs, ranitidine and cimetidine, and sucralfate had equal efficacy for treating reflux esophagitis, although higher grade esophagitis did not heal as well compared to lower grade esophagitis. In foals, sucralfate had a protective effect on oral, esophageal, and gastric ulcers associated with IV administration of high‐dose phenylbutazone .…”

Section: Mechanism Of Action Biological Targets Efficacy Adverse Ementioning

confidence: 89%

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

Marks

Kook

Papich

et al. 2018

Veterinary Internal Medicne

177

View full text Add to dashboard Cite

The gastrointestinal (GI) mucosal barrier is continuously exposed to noxious toxins, reactive oxygen species, microbes, and drugs, leading to the development of inflammatory, erosive, and ultimately ulcerative lesions. This report offers a consensus opinion on the rational administration of GI protectants to dogs and cats, with an emphasis on proton pump inhibitors (PPIs), histamine type‐2 receptor antagonists (H2RAs), misoprostol, and sucralfate. These medications decrease gastric acidity or promote mucosal protective mechanisms, transforming the management of dyspepsia, peptic ulceration, and gastroesophageal reflux disease. In contrast to guidelines that have been established in people for the optimal treatment of gastroduodenal ulcers and gastroesophageal reflux disease, effective clinical dosages of antisecretory drugs have not been well established in the dog and cat to date. Similar to the situation in human medicine, practice of inappropriate prescription of acid suppressants is also commonplace in veterinary medicine. This report challenges the dogma and clinical practice of administering GI protectants for the routine management of gastritis, pancreatitis, hepatic disease, and renal disease in dogs and cats lacking additional risk factors for ulceration or concerns for GI bleeding. Judicious use of acid suppressants is warranted considering recent studies that have documented adverse effects of long‐term supplementation of PPIs in people and animals.

show abstract

Section: Mechanism Of Action Biological Targets Efficacy Adverse Ementioning

confidence: 89%

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

Marks

Kook

Papich

et al. 2018

Veterinary Internal Medicne

177

View full text Add to dashboard Cite

show abstract

“…In most cases, the infection remains latent without causing disease. Reactivation and CMV disease has traditionally been described in populations with marked alterations in cellular immunity (Anderson, 1991). However, in the past two decades there has been increasing evidence to show that reactivation of CMV is a common finding in the immunocompetent critically ill patients (Kalil and Florescu, 2009).…”

Section: Cytomegalovirusmentioning

confidence: 99%

Viral-reactivated pneumonia during mechanical ventilation: is there need for antiviral treatment?

et al. 2011

View full text Add to dashboard Cite

Respiratory viruses are not a common cause of ventilator-associated pneumonia (VAP). Herpesviridae [Herpes simplex virus (HSV) and cytomegalovirus (CMV)] are detected frequently in the lower respiratory tract of ventilated patients. HSV is detected between days 7 and 14 of invasive mechanical ventilation (IMV); presence of the virus does not necessarily imply pathogenicity, but the association with adverse clinical outcomes supports the hypothesis of a pathogenic role in a variable percentage of patients. Bronchopneumonitis associated with HSV should be considered in patients with prolonged IMV, reactivation with herpetic mucocutaneous lesions and those belonging to a risk population with burn injuries or acute lung injury. Reactivation of CMV is common in critically ill patients and usually occurs between days 14 and 21 in patients with defined risk factors. The potential pathogenic role of CMV seems clear in patients with acute lung injury and persistent respiratory failure in whom there is no isolation of bacterial agent as a cause of VAP. The best diagnostic test is not defined although lung biopsies should be considered in addition to the usual methods before starting specific treatment. The role of mimivirus is uncertain and is yet to be defined, but the serologic evidence of this new virus in the context of VAP appears to be associated with adverse clinical outcomes.

show abstract

Medical treatments in the short term management of reflux oesophagitis

Martin¹,

Santana²,

Khan³

et al. 2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Healing of erosive esophagitis with sucralfate and cimetidine: Influence of pretreatment lower esophageal sphincter pressure and serum pepsinogen I levels

Cited by 11 publications

References 22 publications

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

Viral-reactivated pneumonia during mechanical ventilation: is there need for antiviral treatment?

Medical treatments in the short term management of reflux oesophagitis

Contact Info

Product

Resources

About